The overall survival of patients with advanced multiple myeloma (MM) undergoing high-dose chemotherapy and autologous stem cell transplantation (SCT) depends mainly on the quality of response. Thus, to improve the response rate, a new intensified high-dose chemoradiotherapy was evaluated in a phase I/II study. After induction chemotherapy, 89 patients (median age 51 years, range 32-60 years) with MM stage II/III received a conditioning regimen with total marrow irradiation (9 Gy), busulfan (12 mg/kg) and cyclophosphamide (120 mg/kg) followed by SCT. Regimen-related toxicity according to WHO criteria and response rates defined by EBMT/IBMTR were analyzed. The main toxicity was mucositis grade III/IV in 76%, and fever grade 4I in 75% of patients. Three patients developed reversible venoocclusive disease. Transplant-related mortality was 2%. Among patients with de novo and pretreated MM, a CR rate of 48 and 41%, respectively, was documented. With a median follow-up of 45 months, the actuarial median durations of event-free survival (EFS) and overall survival (OS) after transplant were 29 and 61 months for the whole group, 36 and 85 months for patients with de novo MM, respectively. Thus, administration of this intensified conditioning regimen was associated with tolerable toxicity, a high response rate and long EFS and OS.
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Keywords: multiple myeloma; high-dose therapy; total marrow irradiation; busulfan and cyclophosphamide; stem cell transplantation All patients with advanced multiple myeloma (MM) treated with conventional chemotherapy ultimately die of the disease, with less than 3% of patients surviving more than 10 years. [1] [2] [3] High-dose therapy has been shown to improve myeloma cell kill. [4] [5] [6] [7] [8] Furthermore, high-dose therapy followed by autologous bone marrow transplantation improved response rates, disease-free survival and overall survival in comparative studies with standard chemotherapy. [9] [10] [11] The IFM 90 study 9 clearly showed that the quality of response obtained following high-dose chemotherapy determines the duration of disease-free as well as of overall survival of patients with advanced MM. To improve response rates, and consecutively the outcome of these patients, sequential high-dose therapy or intensified conditioning regimens are currently applied in clinical studies. Therefore, in this phase I/II trial, an intensified conditioning regimen followed by autologous peripheral blood stem cell (PBSC) transplantation was evaluated in a multicenter study.
Alkylating agents are active drugs for the treatment of multiple myeloma. There has been considerable interest in combinations of alkylating agents with nonoverlapping extramedullary toxicities as preparative regimens for marrow transplantation. The busulfan-cyclophosphamide (Bu/Cy) combination has shown activity in patients with myeloma undergoing allogeneic bone marrow transplantation. In addition, myeloma cells are highly susceptible to irradiation indicating that this treatment modality might be important for improved tumor control. Thus, Bensinger and co-workers pioneered the addition of total body irradiation (TBI) to Bu and Cy. In phase I/II studies, 12, 13 they showed this regimen to be effective in patients with advanced hematological malignancies. To reduce the hepatic and pulmonary toxicity of this conditioning regimen combining TBI and Bu, shielding of the lung and liver was introduced and the dosage of this modified TBI was reduced to 10.5 and 9 Gy applied in 1.5 Gy fractions twice daily over 3-4 days. This regimen was shown to be effective in patients with advanced MM.
14 To further reduce the significant toxicity of this conditioning regimen, we decided to combine a total dose of 9 Gy of modified TBI (total marrow irradiation, TMI), with a reduced dosage of Bu (12 mg/kg body weight (BW) instead of 16 mg/kg BW) and Cy (120 mg/kg).
We report here the results of a phase I/II study designed to evaluate the toxicity and efficacy of this regimen in patients with advanced MM.
Patients and methods

Patient selection
Patients were referred to the participating centers for consideration of high-dose therapy with hematopoietic stem cell support. Patient records, X-rays and bone marrow aspirates were reviewed to confirm the diagnosis of MM. Patients had to meet the established criteria for active MM according to Durie and Salmon 15 and only patients in stage II or III according to Durie and Salmon were included in the study. Patients who had received more than one line of chemotherapy prior to stem cell mobilization were considered as pretreated (n ¼ 56), in contrast to patients with only one line of chemotherapy prior to stem cell transplantation (de novo MM) (n ¼ 33).
Standard hematologic and chemistry studies were used to evaluate organ function prior to inclusion in the study, as well as during treatment and follow-up.
Patients with a Karnofsky score less than 60, pulmonary diffusion capacity less than 50% of the age-adjusted value, symptomatic heart failure (systolic cardiac ejection fraction o50%), major neurologic disease or infections (HIV, HBV, HCV, uncontrolled bacterial or fungal infections) and/or bilirubin and serum transaminase levels above three times the normal value were excluded. At protocol entry, patients could have renal failure (creatinine 42 mg/dl) or poor performance status related to MM. Renal function had to improve after induction chemotherapy to a creatinine level o2 mg/dl prior to stem cell mobilization.
Each patient who had received prior radiation was evaluated by one of the investigators (radiation-oncologists) to determine whether further radiation to specific organ systems was tolerable. Patients who had received previous dose-limiting local irradiation therapy (435 Gy to cervical or thoracic spine, 440 Gy to lumbar spine) were excluded.
Treatments were performed between September 1994 and August 1998, with end points calculated to the date of last contact (July 1, 2002).
All patients signed an informed consent in keeping with the guidelines of the Institutional Review Board of all the participating centers. The whole treatment program was approved by a local Human Investigations Committee and in accordance with an insurance filed.
Induction chemotherapy
All patients received at least three cycles of induction chemotherapy followed by stem cell mobilization aiming for 42 Â 10 6 CD34+ cells/kg BW. The type of induction therapy is described in the Results section.
Patients with at least 50% reduction in myeloma protein in blood or urine (PR or CR) following VAD or alternative induction regimen were considered to have chemotherapysensitive disease.
Stem cell mobilization
For stem cell mobilization, Cy 4 g/m 2 and G-CSF 10 mg/kg were administered.
High-dose chemoradiotherapy
For intensification of the conditioning regimen, modified TBI (TMI) was added to Bu and Cy. The modified TBI regimen was delivered by a linear accelerator in 1.5-Gy fractions twice daily over 3 days at a dose rate of 0.12 Gy/ min with 90% lung and liver shielding (day À9 to day À7). The minimal interval between fractions was 6 h. Electronbeam treatments of 1.5 Gy were given to rib areas that had been previously shielded at each fraction. Patients received TMI at total doses of 9 Gy. Following TMI, oral Bu 12 mg/ kg (4 Â 1 mg/kg on days À6 to À4) and Cy 120 mg/kg (60 mg/kg on days À3 and À2) were administered.
After a Hickman catheter or other central venous line had been inserted, patients were nursed in single-or twobed rooms from the time they received conditioning therapy with TMI, Bu and Cy until neutrophil recovery and discharge from hospital.
Mesna was administered as a 24-h infusion during the 2 days patients received Cy, to prevent hemorrhagic cystitis.
Following PBSC transplantation (day 0), all patients received granulocyte colony-stimulating factor (G-CSF) (Neupogen s ) treatment (5 mg/kg) beginning on day +1. Oral antimicrobial prophylaxis with ofloxacin 2 Â 200 mg/day, fluconazole 100 mg/day and acyclovir 4 Â 400 mg/day was recommended until discharge. Acyclovir was given intravenously (3 Â 250 mg/m 2 /day) when patients were unable to take oral medication. Intravenous gamma-globulin 200 mg/kg was recommended prior to and every 3 weeks after transplant for 2 months. PcP prophylaxis with trimethoprim-sulfamethoxazole was scheduled until day +60, since immune reconstitution takes about 2-3 months following a single autologous stem cell transplant. Patients who developed febrile neutropenia received broad spectrum antimicrobial therapy. Blood product support was used when hemoglobin concentration dropped below 8 g/dl or platelets below 10 000/ml.
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Maintenance therapy
Maintenance therapy with IFNa in doses of 3 million units subcutaneously three times per week was recommended for all patients alive beyond day 30. IFNa was only started after hematological reconstitution had been documented and patients had recovered from the side effects of highdose chemoradiotherapy.
Follow-up
Patient follow-up was carried out on a daily basis until day +30, and scheduled on a weekly basis until day +100. Serial laboratory parameters and clinical follow-up visits were scheduled at 3-6 months intervals during the first 3 years and subsequently at least every 6 months, to document MM and clinical status as well as late toxicity of the regimens.
Toxicity/response
Regimen-related toxicity according to WHO criteria and response rates (CR, PR) as defined by the EBMT/IBMTR/ ABMTR criteria 16 were analyzed.
Study end points
Primary study end points were toxicity and treatmentrelated mortality (TRM). Secondary end points included response rate, frequency of CR and duration (from onset of CR until progression) as well as event-free survival (EFS) and overall survival (OS). Data were analyzed on an intentto-treat basis.
Statistical analysis
Patient data were documented by the treating centers, monitored by the Department of Hematology and Oncology, Tu¨bingen and transferred to the Institute for Medical Information Processing, which conducted the statistical analyses. The Kaplan-Meier method was used to estimate EFS and OS probabilities, with differences compared by the two-sided log-rank test. EFS was calculated as the interval from date of transplant to the date of last followup or of first event. EFS analysis considered death of any cause as an event, as well as relapse or progression. We planned to perform a multivariate analysis (Cox regression) only if more than one of the potential prognostic factors showed a striking influence on univariate analysis (Po0.1) and a minimum of 10% of the patients remained in every subgroup built by the crosstabulation of the potential prognostic factors. All statistical analyses in this study were carried out for descriptive purposes. Data are presented with two-tailed P-values (unadjusted for multiple comparisons) and 95% confidence intervals for the hazard ratios.
Computations were performed using SAS-PC for Windows (ver. 8.0; SAS Institute Inc., Cary, NC, USA).
Results
Patients
Characteristics of all patients who underwent the whole treatment program are listed in Table 1 . A total of 56 patients were pretreated prior to VAD therapy; 27 had received pretreatment for 41 year, 21 with 41 line of prior therapy. All of them showed PD prior to VAD therapy. Out of 89 patients, 83 received 2-3 cycles of VAD (vincristine 0.4 mg i.v. and doxorubicin 9 mg/m 2 i.v., by continuous infusion every 24 h for 4 days combined with dexamethasone 40 mg orally days 1-4, 9-12 and 17-20) with an interval of 28 days as induction chemotherapy regimen. A total of 33 (40%) patients achieved a PR and two (2%) a CR. Four patients received three, four, six or eight cycles of melphalan/prednisolone and two patients 1-2 cycles of ifosphamide/prednisolone for induction treatment. 
Irrespective of the response to VAD or the alternative induction chemotherapy regimens, all but three patients received high-dose Cy (4 g/m 2 ) administered between 5 and 9 weeks after the last induction course. In all 86 patients, recombinant human G-CSF at a dose of 10 mg/kg/day s.c. was started on day +1 after Cy and continued until stem cell harvest was completed. In three patients who showed a partial remission with less than 5% plasma cells in the marrow aspirate after two cycles of VAD, G-CSF 10 mg/kg was administered after the third cycle of VAD and PBSC collected.
Following Cy treatment, all patients showed at least SD, 54% of patients achieved a PR and two (2%) a CR, respectively. The median number of CD34+ cells collected after Cy (4 g/m 2 ) and G-CSF administration was 3.9 Â 10 6 / kg (range 1.3-16.7 Â 10 6 /kg BW). In seven patients, more than 10 Â 10 6 /kg CD34+ cells were harvested. In only two heavily pretreated patients were less than 2 Â 10 6 /kg CD34+ cells collected. Both these patients decided to receive high-dose treatment and autologous stem cell transplantation. In spite of the low number of CD34+ cells transfused, hematopoietic reconstitution was not delayed in these patients (platelet engraftment within 20 days).
High-dose chemoradiotherapy
Patients received modified TBI (TMI) as described above at total doses of 9 Gy. Following TMI, 76 patients received Bu 12 mg/kg and Cy 120 mg/kg.
In 13 patients, the dosage of oral Bu was reduced by 10-20% due to six patients being considerably overweight (body mass index 428), 17, 18 abnormal lung function tests (n ¼ 3) and dilatative cardiomyopathy (still above the values defined as exclusion criteria) (n ¼ 1), heavy pretreatment and age of 59 years (n ¼ 2), as well as renal dysfunction (creatinine 1.9 mg/dl after aggressive prehydration) (n ¼ 1). PBSC were thawed and infused within 48 h of the last dose of chemotherapy. A median number of 3.9 Â 10 6 CD34+ cells/kg (range 1.3-16.7 Â 10 6 /kg) were infused during stem cell transplantation.
Toxicity
The most common toxicity was severe mucositis WHO grades III/IV in 68/89 (76%) patients (see Table 2 ). Apart from two patients (one with a fatal invasive aspergillosis), no significant pulmonary toxicity occurred. Three (3%) patients developed hepatic veno-occlusive disease VOD, which could be controlled in all three patients by either prostaglandin E infusions (n ¼ 2) or treatment with tissue plasminogen activator (TPA) (n ¼ 1).
Four patients developed skin reactions WHO grade III either due to allergic reactions or due to a biopsy-proven autologous GvHD in two patients that responded to treatment with methylprednisolone (1 mg/kg). Gastrointestinal toxicity (WHO grades III-IV) occurred in five patients, which was rapidly controlled by narcotic antidiarrheals in four of them. Fever WHO grade XI occurred in the majority (66/89; 75%) of patients and responded to broad-spectrum antibiotics in 62 patients. Only four patients received antifungal therapy with amphotericin B (n ¼ 3) or high-dose intravenous fluconazole (n ¼ 1). A detailed evaluation of the toxicity of the TMI/Bu/Cy regimen during the first 30 days post-transplant is presented in Table 2 . All patients were admitted 12 days prior to PBSCT. Days in hospital after stem cell transplantation were a median of 18 (range 9-58) days. Including the period prior to conditioning and the prolonged conditioning therapy, total days in hospital were a median of 30 (range 21-70) days.
One patient died on day +22 post transplant due to invasive aspergillosis. Transplant-related mortality during the first 100 days post transplant was 1/89 (1%). One further patient died due to infection and bleeding complications 124 days post transplant, several months after hematological reconstitution. Thus, TRM of this chemoradiotherapy regimen followed by autologous PBSC transplantation was 2%.
Hematopoietic reconstitution following high-dose chemoradiotherapy
Hematopoietic reconstitution was rapid in the majority of patients, with a median time to neutrophil engraftment of 10 days (range 7-23 days) and to platelet engraftment of 11 days (range 7-58 days). In all, 11 (12%) patients with prolonged hematopoietic reconstitution (420 days until platelet recovery) did not differ significantly from the whole patient group in terms of median age, number of lines and duration of pretreatment, or number of CD34+ cells transfused (data not shown).
Maintenance therapy
IFNa was given for 43 months to 41 of 85 eligible patients (3 Â 3 million units s.c. three times per week). All other patients stopped IFNa treatment due to side effects or disease progression.
When patients who received and tolerated IFNa for at least 3 months were compared to those not receiving or not tolerating IFNa for 3 months, there was a trend toward 
Response to high-dose chemoradiotherapy
All 89 patients responded to high-dose chemoradiotherapy with 39 (44%) of them achieving a CR and 50 (56%) a PR. Among the patients with de novo MM, CR and PR rates were 48% (16/33) and 52% (17/33), respectively, whereas 41% (23/56) of pretreated patients achieved CR and 59% (33/56) PR. A total of 30% (3/10) of patients with an elevated serum LDH level (4190 U/l) and 46% (35/76) of patients with a normal serum LDH level achieved CR (P ¼ 0.50).
There was a trend to a higher CR rate in patients with a b 2 m p2.5 mg% (20/36, 56%) when compared to patients with a b 2 m 42.5 mg% (18/48, 38%) (P ¼ 0.12).
Relapse and death
During follow-up (median 45, range 0-85 months), 58 (65%) of the 89 patients relapsed; 47 (53%) of 89 patients are still alive. In all, 14 out of 21 (67%) patients with 42 lines of pretreatment, 37 out of 56 (66%) patients with pretreatment (at least one line of chemotherapy prior to inclusion in the study) and 21 of 33 (64%) patients with de novo MM relapsed. Relapse rates among patients receiving pretreatment for 41 and o1 year did not differ significantly with 21/33 (64%) and 37/56 (66%), respectively (P ¼ 0.82).
Whereas 37 of 48 (77%) patients with a b 2 m 42.5 mg/l relapsed, these were only 17 of 36 (47%) patients with a b 2 m o2.5 mg/l (P ¼ 0.0047).
EFS and OS following high-dose chemoradiotherapy
At present, 47 (53%) patients are alive and 26 (29%) are event-free at a median follow-up of 56 months (range 21-76 months). A total of 58 (65%) patients have relapsed after a median of 21 (range 2-75) months from transplant. Time to relapse among the patients treated with de novo MM was 28 (range 4-55) months.
OS and EFS for the entire group are shown in Figure 1 . Actuarial median OS is 61 months, median EFS of the entire group is 29 months. The Kaplan-Meier estimates of OS and EFS of the whole patient group at 4 years are 58 and 35%, respectively. OS and EFS for patients with de novo MM are depicted in Figure 2 demonstrating that actuarial median OS is 85 months, median EFS is 36 months. The Kaplan-Meier estimates of OS and EFS at 4 years for de novo MM are 66 and 36%, respectively.
The 4-year EFS for patients with a b 2 m o2.5 mg/l was 54% (36.5-70.4%), in contrast to 21.9% (19.9-33.9%) for the patients with a b 2 m 42.5 mg/l (P ¼ 0.037). For the 10 patients not exhibiting any of the five factors associated with poor prognosis (serum LDH o190 U/l, b 2 m p 2.5 mg/l, CRP p4 mg/l, chemosensitive disease, CR post transplant) with a median follow-up of 56 months. 4-year EFS and OS were found to be 79 and 100%, respectively.
Factors associated with improved EFS and OS
To discern the independent contributions to clinical outcome, two stepwise backward multivariate Cox regression analyses for EFS and OS were computed with 10 factors, of which five (LDH, b 2 m 42.5 mg/l, CRP 44 mg/l, chemoresistant disease, no CR post-transplant) showed a notable influence on both EFS and OS, on univariate analysis (Po0.1) ( Table 3 ). All serological factors (LDH, b 2 m, CRP) were determined prior to inclusion in the study (prior to induction therapy). As there were too few cases in some of the subgroups (o10% of all patients), the results were not sufficiently reliable to reach any conclusions.
Discussion
To improve response rates and outcome of patients with advanced MM, intensification of high-dose therapy is currently evaluated in clinical studies either by the use of sequential high-dose chemotherapy or of intensified conditioning regimens.
Intensification of high-dose chemotherapy by performing sequential cycles of high-dose melphalan followed by autologous stem cell transplantation has been shown to increase the response rate in patients with advanced MM. 19, 20 In this phase I/II study, we evaluated the toxicity and efficacy of a single transplant regimen with increased intensity combining two alkylating agents with nonoverlapping extramedullary toxicities and TMI (a modified TBI). TMI was designed to reduce irradiation of the liver and Total marrow irradiation and Bu/Cy for multiple myeloma H Einsele et al lung by shielding of these organs and thus allowing its combination with high-dose Bu and high-dose Cy.
The combination of high-dose melphalan and conventional TBI failed to show an improved outcome when compared to high-dose melphalan alone. In several phase II studies, results of high-dose melphalan with or without conventional TBI have been comparable. 19, [21] [22] [23] [24] The addition of conventional TBI to melphalan in patients who responded to a first cycle of high-dose melphalan did not lead to higher CR rates. 19, 25 In a recent randomized study, 200 mg/m 2 melphalan was found to be less toxic and at least as effective as conditioning, when compared with 8 Gy TBI and 140 mg/m 2 melphalan. 26 However, there might be some crossresistance between melphalan and irradiation, as demonstrated in several in vitro systems. 27, 28 Thus, we added other chemotherapeutic agents with known antimyeloma activity (Bu, Cy) to the modified TBI schedule in the conditioning regimen evaluated in this study.
With the TMI protocol, 90% liver and lung shielding was introduced when compared to conventional TBI. In addition, in the study presented, the dosage of Bu was reduced from 16 to 12 mg/kg administered on three consecutive days. Probably due to these specific modifications, lung and liver toxicity in this study were only moderate in spite of the combination of two components each associated with lung and liver toxicity. Only three patients developed VOD, which was controllable in all three patients. One patient developed fatal pulmonary aspergillosis on day +22 and one patient died due to infectious and bleeding complications 124 days post transplant, resulting in a TRM of 2%.
The main toxicities observed were severe mucositis in 76% and fever WHO grade 4I in 74% of patients. These toxicities were only slightly higher than those reported for conditioning regimens with high-dose melphalan. 9, 11 No dose-limiting acute toxicity was noted and none of the patients has developed long-term toxicity to date. Although a combination of radiotherapy and two alkylating agents was administered, none of the patients has developed myelodysplasia during the follow-up with a median followup time of 56 months.
One study 25 showed impaired lymphocyte recovery in more intensely conditioned patients, who showed a shorter remission duration suggesting a possible role for immunologic recovery in remission maintenance. In addition, an increased and prolonged risk for infectious complications following a more intensified regimen has to be considered. In the study reported here, the increased intensity of conditioning with a combination of two alkylating agents and modified TBI was associated with acceptable toxicity. The transplant-related mortality of 2% is in the lower range of that reported even for conventional high-dose chemotherapy regimens and autologous stem cell transplantation. 9, 11 This was observed in spite of the fact that a large percentage of patients had been heavily pretreated prior to undergoing stem cell mobilization and finally high-dose chemoradiotherapy.
In spite of the large proportion of pretreated patients, a high CR rate (44%) was achieved following high-dose chemoradiotherapy, which also resulted in long-term EFS (median 29 months) and OS (median 61 months). In patients with de novo MM, the CR rate was 48% and EFS and OS were 36 and 85 months, respectively. Thus, the median EFS and OS with a single autotransplant and an impressive TRM of 2% seems to be equivalent to that of seen with tandem autotransplants. 29 Unfortunately, cytogenetic data are available for only a few patients. Two patients with documented 13q14 deletion on interphase FISH and/or cytogenetics showed an EFS 43 years. 26 Pretransplant variables like b 2 m, CRP and serum LDH level determined prior to induction chemotherapy have been described as having a major impact on response rate, response quality and OS and EFS in other high-dose treatment studies including those using tandem melphalan therapy. [9] [10] [11] 20, 29 In this study, these pretransplant parameters were also found to influence response rate and quality as well as OS and EFS, but because there were few cases in some of the subgroups, no significant correlation could be shown on stepwise backward multivariate Cox regression analysis. In summary, this new intensified conditioning regimen was associated with tolerable toxicity and a TRM in the range reported with less intensive conditioning regimens. Response rate and quality and subsequent EFS and OS (36 and 85 months) in patients with de novo MM look promising but have to be confirmed in comparative studies. 26 Therefore, conditioning therapy with TMI/BU/Cy is currently being compared with tandem 
